Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Salarius Pharmaceuticals Inc SLRX

Healthcare Biotechnology
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and... see more

Recent & Breaking News (NDAQ:SLRX)

Salarius Pharmaceuticals Announces Board of Director Nominations in Advance of 2020 Annual Meeting

GlobeNewswire April 29, 2020

Salarius Pharmaceuticals to Deliver Virtual Presentation at the Emerging Growth Invitational

GlobeNewswire April 22, 2020

Salarius Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results

GlobeNewswire March 23, 2020

Salarius Announces Allowance of New European Patent Covering Seclidemstat

GlobeNewswire March 4, 2020

Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference

GlobeNewswire March 2, 2020

Salarius Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

GlobeNewswire February 11, 2020

Salarius Pharmaceuticals to Present at the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference

GlobeNewswire February 10, 2020

Salarius Announces Pricing of $9.6 Million Underwritten Public Offering

GlobeNewswire February 7, 2020

Salarius Pharmaceuticals to Present at the BIO CEO & Investor Conference

GlobeNewswire February 5, 2020

Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors

GlobeNewswire February 4, 2020

Salarius Pharmaceuticals to Present at Biotech Showcase 2020

GlobeNewswire December 19, 2019

Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression

GlobeNewswire December 17, 2019

Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma

GlobeNewswire December 16, 2019

Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic

GlobeNewswire December 12, 2019

Salarius Pharmaceuticals Reports Three and Nine Month 2019 Financial Results

GlobeNewswire November 13, 2019

Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement

GlobeNewswire October 28, 2019

Salarius Pharmaceuticals to Present at Two Upcoming Investor Conferences

GlobeNewswire October 14, 2019

Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children's Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma

GlobeNewswire October 8, 2019

Salarius Pharmaceuticals Announces Senior Leadership Changes

GlobeNewswire September 13, 2019

Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month

GlobeNewswire September 12, 2019